PTC Completes Enrollment of Phase 3 Clinical Trial of Translarna™ for Patients with Cystic Fibrosis
Go back to PTC Completes Enrollment of Phase 3 Clinical Trial of Translarna™ for Patients with Cystic Fibrosis| PTC THERAPEUTICS (NASDAQ: PTCT) | Delayed: 80.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $80.96 | 52 Week High | $35.40 | |||
| Open | $80.96 | 52 Week Low | $4.03 | |||
| Day High | $80.96 | P/E | 8.61 | |||
| Day Low | $80.96 | EPS | $9.40 | |||
| Volume | 1,077 | |||||
